Source: http://www.google.com/patents/US8222296?dq=7565338
Timestamp: 2016-07-23 19:40:52
Document Index: 394672514

Matched Legal Cases: ['Application No. 02823600', 'Application No. 06756205', 'Application No. 09711260', 'Application No. 02772790', 'Application No. 10182948', 'Application No. 07789958', 'Application No. 02772790', 'Application No. 10182948', 'Application No. 05718914', 'Application No. 09711260', 'Application No. 07789958', 'Application No. 02772790', 'Application No. 10182948', 'Application No. 2008243147', 'Application No. 2006256369', 'Application No. 2004201240', 'Application No. 2004201240', 'Application No. 642', 'Application No. 2006256369', 'Application No. 2007274583', 'Application No. 2004', 'Application No. 187892', 'Application No. 203058', 'Application No. 02823600', 'Application No. 187892', 'Application No. 642', 'Application No. 161083', 'Application No. 161083', 'Application No. 200780033294', 'Application No. 161083', 'Application No. 196538', 'Application No. 196538', 'Application No. 642', 'Application No. 187892', 'Application No. 02823600', 'Application No. 199877', 'Application No. 642', 'Application No. 642', 'Application No. 02823600', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 196538', 'Application No. 200780033294', 'Application No. 2007', 'Application No. 2006256369', 'Application No. 2010', 'Application No. 203058', 'Application No. 161083', 'Application No. 2008243147', 'Application No. 200810190781', 'Application No. 2003', 'Application No. 200580017025', 'Application No. 2007', 'Application No. 09711260', 'Application No. 10182948', 'Application No. 02772790', 'Application No. 2009', 'Application No. 2004', 'Application No. 200680029378', 'Application No. 2009', 'Application No. 07789958', 'Application No. 2', 'Application No. 199877', 'Application No. 199877', 'Application No. 200780033294', 'Application No. 187892', 'Application No. 161083', 'Application No. 187892', 'Application No. 06756205', 'Application No. 02772790', 'Application No. 2010', 'Application No. 2009', 'Application No. 2003', 'Application No. 2010', 'Application No. 2009', 'Application No. 2007', 'Application No. 2003', 'Application No. 2007', 'Application No. 2008', 'Application No. 2004', 'Application No. 2009', 'Application No. 2004', 'Application No. 2010', 'Application No. 200810190781', 'Application No. 200780033294', 'Application No. 200680029378', 'Application No. 200680029378', 'Application No. 200810190781', 'Application No. 200780033294', 'Application No. 200580017025', 'Application No. 200580017025']

Patent US8222296 - Conjugates comprising a GABA- or glycine compound, pharmaceutical ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsConjugates of a gamma-aminobutyric acid (GABA) compound or a glycine compound and an analgesic drug are disclosed. Further disclosed are pharmaceutical compositions containing these conjugates and uses thereof in the treatment of CNS-associated diseases or disorders, optionally in combination with a...http://www.google.com/patents/US8222296?utm_source=gb-gplus-sharePatent US8222296 - Conjugates comprising a GABA- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating CNS disordersAdvanced Patent SearchPublication numberUS8222296 B2Publication typeGrantApplication numberUS 12/373,542PCT numberPCT/IL2007/000902Publication dateJul 17, 2012Filing dateJul 17, 2007Priority dateJul 17, 2006Also published asCA2659521A1, CN101511388A, CN101511388B, EP2051735A2, EP2051735B1, US8377990, US20090304584, US20100144869, US20130059910, WO2008010222A2, WO2008010222A3, WO2008010223A2, WO2008010223A3Publication number12373542, 373542, PCT/2007/902, PCT/IL/2007/000902, PCT/IL/2007/00902, PCT/IL/7/000902, PCT/IL/7/00902, PCT/IL2007/000902, PCT/IL2007/00902, PCT/IL2007000902, PCT/IL200700902, PCT/IL7/000902, PCT/IL7/00902, PCT/IL7000902, PCT/IL700902, US 8222296 B2, US 8222296B2, US-B2-8222296, US8222296 B2, US8222296B2InventorsAbraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman, Ran Lifshitz, Ilan WinklerOriginal AssigneeRamot At Tel-Aviv University Ltd., Bar-Ilan University, Biolinerx Ltd.Export CitationBiBTeX, EndNote, RefManPatent Citations (100), Non-Patent Citations (247), Classifications (9), Legal Events (2) External Links: USPTO, USPTO Assignment, EspacenetConjugates comprising a GABA- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating CNS disorders
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS2914528Apr 16, 1958Nov 24, 1959Smith Kline French LabSubstituted phenothiazinyl trifluoro-methyl sulfonesUS2944053May 23, 1958Jul 5, 1960Smith Kline a French LaboratoriesUiiilcuUS2969358Dec 8, 1958Jan 24, 1961Searle & Co2-chloro-10-phenothiazinecarbonylpiperazinesUS3227708Sep 11, 1957Jan 4, 1966Olin MathiesonTrifluoromethyl phenothiazinesUS3956493Oct 21, 1974May 11, 1976E. R. Squibb & Sons, Inc.Long acting tranquilizing agentUS3966930May 30, 1974Jun 29, 1976Kefalas A/SPhenothiazine derivatives, compositions thereof and methods of preparation thereofUS3978216Jul 16, 1975Aug 31, 1976Nelson Research & Development CompanyMethod for treating schizophrenia and method and composition for potentiating neuroleptic drugsUS4153694Aug 19, 1977May 8, 1979Kefalas A/SBehenic acid esters, compositions thereof and a method of preparation thereofUS4629691Aug 12, 1983Dec 16, 1986Syntex (U.S.A.) Inc.Tricyclic antidepressant conjugates with antigens and enzymesUS4818936Feb 17, 1986Apr 4, 1989The Broken Hill Proprietary Company LimitedMethod and apparatus for identifying and classifying steelsUS5051448May 7, 1990Sep 24, 1991The Mclean Hospital CorporationGABA esters and GABA analog estersUS5145684Jan 25, 1991Sep 8, 1992Sterling Drug Inc.Surface modified drug nanoparticlesUS5525727Oct 28, 1992Jun 11, 1996University Of FloridaBrain-specific drug deliveryUS5828405Nov 8, 1996Oct 27, 1998Omphalos Recovery Systems Inc.Gemstone registration systemUS5966673Jan 10, 1997Oct 12, 1999Diamond Technologies, Inc.System and method for computerized evaluation of gemstonesUS5983238Dec 26, 1997Nov 9, 1999Diamond IdGemstons identification tracking and recovery systemUS5994392Jun 5, 1995Nov 30, 1999Neuromedica, Inc.Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acidUS6020954May 28, 1998Feb 1, 2000Imagestatistics, Inc.Method and associated apparatus for the standardized grading of gemstonesUS6121325Mar 27, 1997Sep 19, 2000Merck & Co., Inc.Naphthyl compounds promote release of growth hormoneUS6197764Nov 26, 1997Mar 6, 2001Protarga, Inc.Clozapine compositions and uses thereofUS6239867Dec 7, 1999May 29, 2001Imagestatistics, Inc.Apparatus and method for grading, testing, and identifying gemstonesUS6294562Apr 29, 1999Sep 25, 2001Hoechst AktiengesellschaftSalts of ethyl 3-(2-(4-(4-amino-imino-methyl)phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl)acetylamino)-3-phenylpropionateUS6304853Sep 21, 1998Oct 16, 2001Peter J. MalnekoffAutomated gemstone evaluation systemUS6381510Nov 19, 1999Apr 30, 2002Eruggallery.ComMethods and apparatus for facilitating electronic commerce in area rugsUS6569853Nov 6, 2000May 27, 2003Combinatorx, IncorporatedCombinations of chlorpromazine and pentamidine for the treatment of neoplastic disordersUS7544681Mar 25, 2004Jun 9, 2009Ramot At Tel Aviv University Ltd.Conjugated psychotropic drugs and uses thereofUS7598239Dec 27, 2007Oct 6, 2009Ramot At Tel Aviv University Ltd.Conjugated psychotropic drugs and uses thereofUS7619006Dec 11, 2006Nov 17, 2009Ramot At Tel Aviv University Ltd.Conjugated psychotropic drugs and uses thereofUS7939525Sep 1, 2009May 10, 2011Bar-Ilan UniversityConjugated psychotropic drugs and uses thereofUS20010024532Jun 1, 2001Sep 27, 2001Malnekoff Peter J.Automated gemstone evaluation systemUS20020010208May 1, 2001Jan 24, 2002Victor ShashouaDha-pharmaceutical agent conjugates of taxanesUS20020021439Aug 6, 2001Feb 21, 2002Derek PriestleyColour matching systemUS20020052170Jun 18, 2001May 2, 2002Holloway Garry I.System and method of gem evaluationUS20030065586Jul 31, 2001Apr 3, 2003Shaftel Keith L.Electronic commerce product pricing and selection system and methodUS20030115079Aug 14, 2002Jun 19, 2003Rapaport Martin M.Method of and system for ranking optimal valuesUS20040068417Aug 11, 2003Apr 8, 2004Menahem SevdermishMethod for digital color grading of gems and communication thereofUS20040092504Nov 12, 2002May 13, 2004Anuthep Benja-AthonDefinitive medications for treating fibromyalgiaUS20040242570Mar 25, 2004Dec 2, 2004Abraham NudelmanConjugated psychotropic drugs and uses thereofUS20050149369Mar 3, 2005Jul 7, 2005Menahem SevdermishMethod for digital color grading of gems and communication thereofUS20060046967 *Aug 26, 2005Mar 2, 2006Apparao SatyamProdrugs containing novel bio-cleavable linkersUS20060058219Dec 27, 2004Mar 16, 2006Miller Landon CAminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disordersUS20060142181Dec 27, 2004Jun 29, 2006Miller Landon CCompound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexesUS20070099977Dec 11, 2006May 3, 2007Ramot At Tel Aviv University Ltd.Conjugated psychotropic drugs and uses thereofUS20070197514Dec 11, 2006Aug 23, 2007Ramot At Tel Aviv University Ltd.Conjugated psychotropic drugs and uses thereofUS20070219181Mar 8, 2007Sep 20, 2007Eisai R&D Management Co., Ltd.Multi-cyclic cinnamide derivativesUS20080108606Dec 27, 2007May 8, 2008Ramot At Tel Aviv University Ltd.Conjugated psychotropic drugs and uses thereofUS20090215809Jan 23, 2009Aug 27, 2009Xenoport, Inc.Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of useUS20090298814Jun 7, 2006Dec 3, 2009Ramot At Tel Aviv Univeristy LtdNovel salts of conjugated psychotropic drugs and processes of preparing sameUS20090304584Jul 17, 2007Dec 10, 2009Ramot At Tel Aviv University Ltd.Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disordersUS20100063034Mar 11, 2010Ramot At Tel Aviv University Ltd.Conjugated psychotropic drugs and uses thereofUS20100120755Jan 14, 2010May 13, 2010Ramot At Tel Aviv University Ltd.Conjugated psychotropic drugs and uses thereofUS20100204469Apr 21, 2010Aug 12, 2010Ramot At Tel Aviv University Ltd.Conjugated psychotropic drugs and uses thereofUS20110312948Dec 22, 2011Abraham NudelmanCrystalline Forms of the Tri-Mesylate Salt of Perphenazine-Gaba and Process of Producing the SameCA2461663A1Sep 29, 2002Apr 3, 2003Ramot At Tel Aviv University Ltd.Conjugated anti-psychotic drugs and uses thereofCN1596141ASep 29, 2002Mar 16, 2005特拉维夫大学拉莫特有限公司Conjugated anti-psychotic drugs and uses thereofEP0361485A2Sep 28, 1989Apr 4, 1990Yale UniversityA method of sensitizing multidrug resistant cells to antitumor agentsES8707175A1 Title not availableGB829246A Title not availableGB1460713A Title not availableGB1514312A Title not availableGB2159636A Title not availableGB2188630A Title not availableGB2358541A Title not availableJP2000020681A Title not availableJP2001201454A Title not availableJP2001501965A Title not availableJP2001519754A Title not availableJP2005097120A Title not availableJP2005503423A Title not availableJPH0317076A Title not availableJPH1059948A Title not availableJPH02128564A Title not availableJPH02188527A Title not availableJPH11506723A Title not availableJPS5025574A Title not availableJPS5350185A Title not availableJPS6072868A Title not availableJPS62240660A Title not availableJPS62501991A Title not availableWO1986004991A1Feb 17, 1986Aug 28, 1986The Broken Hill Proprietary Company LimitedClassification of steelWO1993012496A1Dec 8, 1992Jun 24, 1993Gem International Network, Inc.Computer imaging system for gemstonesWO1996040687A1May 13, 1996Dec 19, 1996Warner-Lambert Company(r)-(z)-1-azabicyclo[2.2.1]heptan-3-one,o-[3-(3-methoxyphenyl)-2-propynyl]oxime maleate as a pharmaceutical agentWO1997002819A1Jul 11, 1996Jan 30, 1997Anormed Inc,2-[2-(dimethylamino)ethyl]-8,8-dipropyl-2-azaspiro[4.5]decane dimaleateWO1997044063A2May 22, 1997Nov 27, 1997Neuromedica, Inc.Dha-pharmaceutical agent conjugatesWO1998017678A1Aug 15, 1997Apr 30, 1998Rhone-Poulenc Rorer Pharmaceuticals Inc.Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptidesWO1998052898A1May 19, 1998Nov 26, 1998Nymox CorporationPharmaceutical agents for the treatment of cerebral amyloidosisWO1999026661A1Nov 16, 1998Jun 3, 1999Protarga Inc.A covalent conjugate of clozapine with a fatty acid and its use for treating schizophreniaWO2001091011A1May 23, 2001Nov 29, 2001Hendry David W JrSystem and method for appraising and describing jewelry and other valuable itemsWO2002028881A1Oct 5, 2001Apr 11, 2002Xenoport, Inc.Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administrationWO2002043652A2Nov 29, 2001Jun 6, 2002Ramot At Tel-Aviv University Ltd.Anti-proliferative drugsWO2003026563A2Sep 29, 2002Apr 3, 2003Ramot At Tel Aviv University Ltd.Conjugated anti-psychotic drugs and uses thereofWO2003061656A1Jan 10, 2003Jul 31, 2003Endo Pharmaceuticals Inc.Pharmaceutical composition and method for treating disorders of the central nervous systemWO2003062942A2Dec 31, 2002Jul 31, 2003Menahem SevdermishA method for digital color grading of gems and communication thereofWO2005032474A2Sep 30, 2004Apr 14, 2005New River Pharmaceuticals Inc.Pharmaceutical compositions for prevention of overdose or abuseWO2005092392A2Mar 27, 2005Oct 6, 2005Ramot At Tel Aviv University Ltd.Conjugated psychotropic drugs and uses thereofWO2006027711A2Aug 26, 2005Mar 16, 2006Nicholas Piramal India LimitedProdrugs and codrugs containing bio- cleavable disulfide linkersWO2006058219A2Nov 23, 2005Jun 1, 2006Interdigital Technology CorporationEmbedding location information in content objectsWO2006131923A2Jun 7, 2006Dec 14, 2006Ramot At Tel Aviv University Ltd.Novel salts of conjugated psychotropic drugs and processes of preparing sameWO2007050318A2Oct 12, 2006May 3, 2007Duke UniversityLipidomics approaches for central nervous system disordersWO2007139818A2May 22, 2007Dec 6, 2007The Board Of Trustees Of The Leland Stanford Junior UniversityPharmacological treatment of cognitive impairment* Cited by examinerNon-Patent CitationsReference1"New Edition of Pharmaceutics", People's Hygiene Publishing House, 14: 178, 1998. Abstract in Chinese Only!2Advisory Action Before the Filing of an Appeal Brief Dated Jan. 10, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/655,048.3Advisory Action Before the Filing of an Appeal Brief Dated Oct. 25, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/764,124.4Bastin et al. "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities", Organic Process Research & Development, 4: 427-435, 2000.5BioLineRx "BioLineRx Announces Positive Topline Results for BL-1020, A First in Class GABA Enhanced Antipsychotic for the Treatment of Schizophrenia. BL-1020 Meets Primary and Secondary Efficacy Endpoints From the Pahase 2b EAGLE Trial", BioLine Rx, 4 P., Sep. 14, 2009.6 *Bousquet et al. "Synthesis, Physical properties, toxicological studies and bioavailability of L-pyroglutamic and L-glutamic acid esters of paracetamol as potentially useful prodrugs," J. Pharm. Pharmacol. 1996, vol. 48, pp. 479-485.7Budavari et al. "The Merck Index", Merck & Co., USA, 12th Ed, 1996, p. 1260. p. 1260, � 1.8Budavari et al. "The Merck Index", Merck & Co., USA, 12th Ed., 1996, p. 1246. p. 1246, Last �.9Budavari et al. "The Merck Index", Merck & Co., USA, 12th Ed., 1996, P.THER-8, First Col., 6th Line From the Bottom, 2nd Col., Line 13.. P.THER-8, First Col., 6th Line From the Bottom, 2nd Col., Line 13.10Capasso et al. "Anticonvulsive Activity of a New GABA Mimetic Drug", European Neuropsychopharmacology, 7: 57-63, 1997.11Carducci et al. "Phenylbutyrate Induces Apoptosis in Human Prostate Cancer and Is More Potent Than Phenylacetate", Clinical Cancer Research, XP002613699, 2(2): 379-387, 1996. Abstract.12Chan et al. "Phenothiazine Inhibitors of Trypanothione Reductase as Potential Antitrypanosomal and Antileishmanial Drugs", Journal of medicinal Chmeistry, 41(2): 148-156, 1998.13Chinese Official Action Dated Aug. 8, 2008 From Patent Office of the Peoples Republic of China Re.: Application No. 02823600.9.14Communication Pursuant to Article 94(3) Dated Apr. 2, 2008 From the European Patent Office Re.: Application No. 06756205.8.15Communication Pursuant to Article 94(3) EPC Dated Apr. 11, 2011 From the European Patent Office Re. Application No. 09711260.1.16Communication Pursuant to Article 94(3) EPC Dated Dec. 16, 2010 From the European Patent Office Re. Application No. 02772790.8.17Communication Pursuant to Article 94(3) EPC Dated Jan. 26, 2012 From the European Patent Office Re. Application No. 10182948.9.18Communication Pursuant to Article 94(3) EPC Dated Nov. 24, 2010 From the European Patent Office Re. Application No. 07789958.1.19Communication Pursuant to Article 96(2) EPC Dated Nov. 24, 2006 From the European Patent Office Re.: Application No. 02772790.8.20Communication Pursuant to Rules 70(2) and 70a(2) EPC Dated Jan. 31, 2011 From the European Patent Office Re. Application No. 10182948.9.21Communication Relating to the Results of the Partial International Search Dated Jun. 13, 2006 From the International Searching Authority Re.: Application No. PCT/IL2005/000341.22Communication Relating to the Results of the Partial International Search Dated May 10, 2007 From the International Searching Authority Re.: Application No. PCT/IL2006/000666.23Communication Relating to the Results of the Partial International Search Dated Nov. 20, 2007 From the International Searching Authority Re.: Application No. PCT/IL2007/000902.24Communication Relating to the Results of the Partial International Search Dated Nov. 27, 2007 From the International Searching Authority Re.: Application No. PCT/IL2007/000903.25Communication Under Rule 112 EPC Dated Oct. 2, 2007 From the European Patent Office Re.: Application No. 05718914.4.26Communication Under Rule 71(3) EPC Dated Feb. 20, 2012 From the European Patent Office Re. Application No. 09711260.1.27Communication Under Rule 71(3) EPC Dated Nov. 28, 2011 From the European Patent Office Re. Application No. 07789958.1.28Communication Under Rule 71(3) EPC Dated Sep. 21, 2011 From the European Patent Office Re. Application No. 02772790.8.29Coradini et al. "Effect of Sodium Butyrate on Human Breast Cancer Cell Lines", Cell Proliferation, XP002613698, 30(3-4) Mar. 1997. Abstract.30Degrand et al. "Synthesis of Nitroxides for Use as Procationic Labels and Their Incorporation Into Nafion Films", The Journal of Organic Chemistry, 58(9): 2573-2577, 1993.31Dutta et al. "Existing Dopaminergic Therapies for Parkinson's Disease", Expert Opinion on Therapeutic Patents, XP002531574, 16: 1613-1625, 2006. � [04.1], Fig. 1.32English Summary of Examination Report Dated Sep. 4, 2007 From the Instituto Mexicano de la Propriedad Industrial Re. Application No. PA/a/2004/002912.33European Search Report and the European Search Opinion Dated Dec. 30, 2010 From the European Patent Office Re. Application No. 10182948.9.34Examination Report Dated Aug. 25, 2010 From the Instituto Mexicano de la Propriedad Industrial Re. Application No. PA/a/2004/002912 and its Summary in English.35Examination Report Dated Dec. 5, 2011 From the Instituto Mexicano de la Propriedad Industrial Re. Application No. MX/a/2009/000641 and Its Summary in English.36Examination Report Dated Jan. 19, 2012 From the Instituto Mexicano de la Propriedad Industrial Re. Application No. MX/a/2007/015511 and Its Translation Into English.37Examination Report Dated Jun. 16, 2011 From the Instituto Mexicano de la Propriedad Industrial Re. Application No. PA/a/2006/010924.38Examination Report Dated Jun. 8, 2011 From the Instituto Mexicano de la Propriedad Industrial Re. Application No. MX/a/2007/015511 and Its Summary Into English.39Examination Report Dated May 30, 2011 From the Instituto Mexicano de la Propriedad Industrial Re. Application No. PA/a/2004/002912 and Its Summary in English.40Examination Report Dated Sep. 20, 2010 From the Instituto Mexicano der la Propriedad Industrial Re. Application No. MX/a/2007/015511 and Its Translation Into English.41Examiner's Report Dated Feb. 24, 2010 From the Australian Government, IP Australia Re.: Application No. 2008243147.42Examiner's Report Dated Jan. 24, 2012 From the Australian Government, IP Australia Re. Application No. 2006256369.43Examiner's Report Dated May 2, 2007 From the Australian Government Re.: Application No. 2004201240.44Examiner's Report Dated May 2, 2007 From the Australian Government, IP Australia Re.: Application No. 2004201240.45Examiner's Report Dated May 23, 2007 From the Government of India Patent Office Re.: Application No. 642/CHENP/2004-SPS.46Examiner's Report Dated Oct. 21, 2010 From the Australian Government, IP Australia Re. Application No. 2006256369.47Examiner's Report Dated Oct. 7, 2011 From the Australian Government, IP Australia Re. Application No. 2007274583.48Fingl et al. "General Principles", The Pharmacological Basis of Therapeutics, Chap.1: 1-46, 1975.49Florence et al. "Prolongation of the Action of Intramuscular Formulations of Phenothiazines", Optimization of Drug Delivery, 17th Alfred Benzon Symposium, Mungsgaard, Copenhagen, p. 93-111, 1982.50Geyer et al. "Animal Behavior Models of the Mechanisms Underlying Antipsychotic Atypicality", Progress in Neuro-Psychopharmacology & Biological Psychiatry, 27: 1071-1079, 2003.51Gil-Ad et al. "Novel Anti-Psychotics That Display GABAergic Acitivity and Decreased Extrapyramidal Side Effects, for the Treatment of Schizophrenia and Related Psychiatric Disorders", Neural Plasticity, 10(3): 200, 2003. Abstract.52Hadad et al. "Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Derivatives of GABA and Glycine", Pharmaceutical Research, 112(6): 905-910, 1995.53International Preliminary Examination Report Dated Oct. 12, 2006 From the International Searching Authority by Patent Cooperation Treaty Re.: Application No. PCT/IL2005/000341.54International Preliminary Report on Patentability Dated Aug. 26, 2010 From the International Bureau of WIPO Re. Re. Application No. PCT/IL2009/000158.55International Preliminary Report on Patentability Dated Dec. 3, 2007 From the International Preliminary Examining Authority Re.: Application No. PCT/IL2006/000666.56International Preliminary Report on Patentability Dated Jan. 29, 2009 From the International Bureau of WIPO Re.: Application No. PCT/IL2007/000902.57International Preliminary Report on Patentability Dated Jan. 29, 2009 From the International Bureau of WIPO Re.: Application No. PCT/IL2007/000903.58International Preliminary Report on Patentability Dated Oct. 12, 2006 From the International Bureau of WIPO Re.: Application No. PCT/IL2005/000341.59International Preliminary Report on Patentability Dated Oct. 17, 2007 From the International Preliminary Examining Authority Re.: Application No. PCT/IL2006/000666.60International Search Report and the Written Opinion Dated Dec. 1, 2011 From the International Searching Authority Re. Application No. PCT/IB2011/000915.61International Search Report and the Written Opinion Dated Dec. 3, 2007 From the International Searching Authority Re.: Application No. PCT/IL2006/000666.62International Search Report and the Written Opinion Dated Feb. 8, 2012 From the International Searching Authority Re.: Application No. PCT/IL2011/000752.63International Search Report and the Written Opinion Dated Mar. 30, 2011 From the International Searching Authority Re. Application No. PCT/IL2010/01041.64International Search Report Dated Aug. 23, 2006 From the International Searching Authority Re.: Application No. PCT/IL2005/000341.65International Search Report Dated Feb. 12, 2008 From the International Searching Authority Re.: Application No. PCT/IL2007/000903.66International Search Report Dated Feb. 13, 2008 From the International Searching Authority Re.: Application No. PCT/IL2007/000902.67International Search Report Dated Jul. 11, 2003 From the International Searching Authority Re.: Application No. PCT/IL02/00795.68International Search Report Dated Jun. 25, 2009 From the International Searching Authority Re.: Application No. PCT/IL2009/000158.69Interview Summary Dated Jan. 27, 2011 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/585,021.70Interview Summary Dated May 6, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/656,048.71Invitation to Pay Additional Fees Dated Jun. 13, 2006 From the International Searching Authority Re.: Application No. PCT/IL2005/000341.72Invitation to Pay Additional Fees Dated Nov. 20, 2007 From the International Searching Authority Re.: Application No. PCT/IL2007/000902.73Invitation to Pay Additional Fees Dated Nov. 27, 2007 From the International Searching Authority Re.: Application No. PCT/IL2007/000903.74K�pf-Maier et al. "An Organoid Culture Assay (OCA) for Determining the Drug Sensitivity of human Tumors", Int. J. Cancer, 51: 99-107, 1992.75Lloyd et al. "The Potential Use of GABA Agonists in Psychiatric Disorders: Evidence From Studies With Progabide in Animal Models and Clinical Trials", Pharmacology, Biochemistry & Behavior, 18: 957-966, 1983.76Luo "Pharmacokinetic Studies of Fluphenazine and Four Ester Prodrugs", A Thesis Submitted to the College of Graduate Studies and Research in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the College of Pharmacy and Nutrition, University Saskatchewan, Saskatoon, Saskatchewan, Canada, p. 1-171, 1999.77Luo et al. "Comparative Pharmacokinetic Analysis of Fluphenazine and Four Ester Prodrugs", Pharmaceutical Research, XP008130430, 14(11 Suppl.): S360, # 2441, Nov. 1997. & Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, MA, USA, Nov. 2-6, 1997.78McCaffrey et al. "A Rapid Fluorometric DNA Assay for the Measurement of Cell Density and Proliferation In Vitro", In Vitro Cellular Development Biology, 24(3): 247-252, 1988. Abstract.79Merck "Schizophrenia", the Merck Manuals, Section Psychiatric Disorders, 17th Ed.: 1569-1575, Dec. 10, 1999. Japanese Version and Its Translation Into English. p. 1572, Right Col., Line 15—p. 1573, Left Col., Line 11, p. 1574, Table 193-1.80Milovic "Effect of Structural Analogues of Propionate and Butyrate on Colon Cancer Cell Growth", International Journal of Colorectal Disease, XP002613700, 15(5-6): 264-270, 2000. Abstract, p. 267, Table 2.81Morissette et al. "High-Througput Crystallization: Polymorphs, Salts, Co-Crystals and Solvates of Pharmaceutical Solids", Advanced Drug Delivery Reviews, 56: 275-300, 2004.82Napolitano et al. "New Directions in Parkinson's Research and Treatment", Expert Opinion on Therapeutic Patents, XP002531575, 8: 1251-1268, 1998. Fig.4.83Nicoletti et al. "A Rapid and Simple Method for Measuring Thymocyte Apoptosis by Propidium Iodide Staining and Flow Cytometry", Journal of Immunological Methods, 139: 271-279, 1991.84Nordenberg et al. "Effects of Psychotropic Drugs on Cell Proliferation and Differentiation", Biochemical Pharmacology, 58: 1229-1236, 1999.85Notice of Allowance Dated Dec. 1, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/764,124.86Notice of Allowance Dated Feb. 23, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/867,055.87Notice of Allowance Dated Jul. 10, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/636,599.88Notice of Allowance Dated Mar. 11, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/808,541.89Notice of Allowance Dated Mar. 21, 2011 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/585,021.90Notice of Allowance Dated May 29, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/005,342.91Notice of the Reason for Rejection Dated Mar. 26, 2010 From the Korean Intellectual Property Office Re.: Application No. 2004-7004581. Korean Only.92Office Action Dated Apr. 17, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/636,594.93Office Action Dated Apr. 25, 2010 From the Israel Patent Office Re.: Application No. 187892 and Its Translation Into English.94Office Action Dated Aug. 23, 2010 From the Israel Patent Office Re. Application No. 203058 and Its Translation Into English.95Office Action Dated Aug. 8, 2008 From the Patent Office of the People's Republic of China Re.: Application No. 02823600.9.96Office Action Dated Dec. 12, 2011 From the Israel Patent Office Re.: Application No. 187892 and Its Translation Into English.97Office Action Dated Feb. 1, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/808,541.98Office Action Dated Feb. 14, 2008 From the Government of India Patent Office Re.: Application No. 642/CHENP/2004-SPS.99Office Action Dated Feb. 15, 2009 From the Israeli Patent Office Re.: Application No. 161083.100Office Action Dated Feb. 27, 2009 From the Israeli Patent Office Re.: Application No. 161083 and Its Translation Into English.101Office Action Dated Jul. 25, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/808,541.102Office Action Dated Jun. 19, 2008 From the US Patent Office Re.: U.S. Appl. No. 11/636,599.103Office Action Dated Jun. 24, 2011 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200780033294.6 and Its Translation Into English.104Office Action Dated Jun. 6, 2010 From the Israeli Patent Office Re.: Application No. 161083 and Its Translation Into English.105Office Action Dated Mar. 2, 2011 From the Israel Patent Office Re. Application No. 196538 and Its Translation Into English.106Office Action Dated Mar. 2, 2011 From the Israeli Patent Office Re. Application No. 196538.107Office Action Dated Mar. 30, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/808,541.108Office Action Dated May 15, 2008 From the Government of India Patent Office Re.: Application No. 642/CHENP/2004-SPS.109Office Action Dated May 16, 2008 From the US Patent Office Re.: U.S. Appl. No. 11/636,594.110Office Action Dated May 17, 2011 From the Israel Patent Office Re.: Application No. 187892 and Its Translation Into English.111Office Action Dated May 9, 2008 From the US Patent Office Re.: U.S. Appl. No. 11/636,599.112Office Action Dated Sep. 9, 2005 From the Patent Office of the People's Republic of China Re.: Application No. 02823600.9 and Its Translation Into English.113Office Action of Jul. 27, 2010 From the Israel Patent Office Re.: Application No. 199877 and Its Translation Into English.114Official Action Dated Apr. 17, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/636,594.115Official Action Dated Aug. 25, 2010 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/764,124.116Official Action Dated Aug. 25, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/655,048.117Official Action Dated Aug. 5, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/764,124.118Official Action Dated Dec. 14, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/585,021.119Official Action Dated Feb. 1, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/808,541.120Official Action Dated Feb. 14, 2008 From the Government of India Patent Office Re.: Application No. 642/CHENP/2004-SPS.121Official Action Dated Feb. 16, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/585,021.122Official Action Dated Feb. 17, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/636,599.123Official Action Dated Feb. 2, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/655,048.124Official Action Dated Jan. 31, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/309,361.125Official Action Dated Jan. 31, 2012 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/034,453.126Official Action Dated Jan. 6, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/656,048.127Official Action Dated Jul. 12, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/921,578.128Official Action Dated Jul. 25, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/808,541.129Official Action Dated Jun. 17, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/585,021.130Official Action Dated Jun. 19, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/636,599.131Official Action Dated Mar. 14, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/764,124.132Official Action Dated Mar. 30, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/808,541.133Official Action Dated May 15, 2008 From the Government of India Patent Office Re.: Application No. 642/CHENP/2004-SPS.134Official Action Dated May 16, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/636,594.135Official Action Dated May 9, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/636,599.136Official Action Dated Nov. 1, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/921,578.137Official Action Dated Nov. 22, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/309,361.138Official Action Dated Oct. 31, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/005,342.139Official Action Dated Oct. 31, 2008 From the US Patent Office Re.: U.S. Appl. No. 12/005,342.140Official Action Dated Sep. 16, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/005,342.141Official Action Dated Sep. 16, 2008 From the US Patent Office Re.: U.S. Appl. No. 12/005,342.142Official Action Dated Sep. 9, 2005 From the Patent Office of the People's Republic of China Re.: Application No. 02823600.9 and Its Translation Into English.143Ogiso et al. "Pharmacokinetic Analysis of Phenytoin and Its Derivatives in Plasma and Brain in Rats", Biological and Pharmaceutical Bulletin, XP002613683, 16(10): 1025-1030, Oct. 1, 1993.144Partial International Search Report Dated Nov. 20, 2007 From the International Searching Authority Re.: Application No. PCT/IL2007/000902.145Partial International Search Report Dated Nov. 27, 2007 From the International Searching Authority Re.: Application No. PCT/IL2007/000903.146Partial International Search Report Jun. 13, 2006 From the International Searching Authority Re.: Application No. PCT/IL2005/000341.147Pouzet et al. "Effects of the 5-HT7 Receptor Antagonist SB-258741 in Animal Models for Schizophrenia", Pharmacology, Biochemistry and Behavior, 71: 655-665, 2002.148Prasad "Butyric Acid: A Small Fatty Acid With Diverse Biological Functions", Life Science, 27(15): 1351-1358, 1980.149Quadri et al. "Effects of Centrally Acting Drugs on Serum Prolactin Levels in Rhesus Monkeys", Neuroendocrinology, 27(3-4): 136-147, 1978. Abstract.150Rephaeli et al. "Gamm-Aminobutyric Acid Amides of Nortriptyline and Fluoxetine Display Improved Pain Suppressing Activity", Journal of Medicinal Chemistry, XP002668033, 52(9): 3010-3017, 2009. Scheme 1, Experimental Section.151Rephaeli et al. "Observation of Sequence-Dependent Interaction Between Prodrugs of Carboxylic-Acid-Esters and Doxorubicin in Cancer Cells", Proceedings of the American Association for Cancer Research, Annual Meeting, 40: 592-, 1999. Abstract. & 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, USA, 1999.152Requisition by the Examiner Dated Aug. 2, 2011 From the Canadian Intellectual Property Office Re. Application No. 2,461,663.153Requisition by the Examiner Dated Aug. 2, 2011 From the Canadian Intellectual Property Office Re. Application No. 2,560,905.154Requisition by the Examiner Dated Nov. 8, 2010 From the Canadian Intellectual Property Office Re. Application No. 2,461,663.155Response Dated Aug. 2, 2011 to Office Action of Mar. 2, 2011 From the Israeli Patent Office Re. Application No. 196538.156Response Dated Aug. 22, 2011 to Office Action of Jun. 24, 2011 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200780033294.6.157Response Dated Dec. 14, 2011 to Notice of Reason for Rejection of Sep. 30, 2011 From the Japanese Patent Office Re. Application No. 2007-504560.158Response Dated Dec. 15, 2011 to Examiner's Report of Oct. 21, 2010 From the Australian Government, IP Australia Re. Application No. 2006256369.159Response Dated Dec. 20, 2010 to Notice of the Reason for Rejection of Oct. 28, 2010 From the Korean Itellectual property Office Re. Application No. 2010-7016372.160Response Dated Dec. 23, 2010 to Office Action of Aug. 23, 2010 From the Israel Patent Office Re. Application No. 203058.161Response Dated Dec. 3, 2007 to Official Action of Feb. 1, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/808,541.162Response Dated Dec. 30, 2009 to Office Action of Aug. 31, 2009 From the Israel Patent Office Re.: Application No. 161083.163Response Dated Feb. 18, 2011 to Examination Report Dated Sep. 20, 2010 From the Instituto Mexicano der la Propriedad Industrial Re.. Application No. MX/a/2007/015511 and Its Translation Into English.164Response Dated Feb. 23, 2011 to Examiner's Report of Feb. 24, 2010 From the Australian Government, IP Australia Re.: Application No. 2008243147.165Response Dated Feb. 24, 2009 to Official Action of Oct. 31, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/005,342.166Response Dated Feb. 25, 2011 to Official Action of Aug. 25, 2010 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/764,124.167Response Dated Feb. 9, 2011 to Office Action of Aug. 11, 2010 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200810190781.X.168Response Dated Jan. 13, 2010 to Notice for Reason for Rejection of Oct. 20, 2009 From the Japanese Patent Office Re.: Application No. 2003-530202.169Response Dated Jan. 13, 2010 to Office Action of Jul. 17, 2009 From the State Intellectual Property Office of the People's Republic of China Re.: Application No. 200580017025.1.170Response Dated Jan. 18, 2011 to Notice of Reason for Rejection of Nov. 2, 2010 From the Japanese Patent Office Re. Application No. 2007-504560.171Response Dated Jul. 24, 2011 to Communication Pursuant to Article 94(3) EPC of Apr. 11, 2011 From the European Patent Office Re. Application No. 09711260.1.172Response Dated Jul. 26 to Communication Pursuant to Rules 70(2) and 70a(2) EPC of Jan. 31, 2011 From the European Patent Office Re. Application No. 10182948.9.173Response Dated Jul. 26, 2011 to Official Action of Mar. 14, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/764,124.174Response Dated Jul. 6, 2011 to Official Action of Mar. 14, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/764,124.175Response Dated Jun. 16, 2011 to Communication Pursuant to Article 94(3) EPC of Dec. 16, 2010 From the European Patent Office Re. Application No. 02772790.8.176Response Dated Jun. 23, 2010 to Notice of the Reason for Rejection of Feb. 24, 2010 From the Korean Intellectual Property Office Re.: Application No. 2009-7024590.177Response Dated Jun. 23, 2010 to Notice of the Reason for Rejection of Mar. 26, 2010 From the Korean Intellectual Property Office Re.: Application No. 2004-7004581.178Response Dated Jun. 6, 2010 to Office Action of Jan. 29, 2010 From the State Property Office of the People's Republic of China Re.: Application No. 200680029378.8.179Response Dated Jun. 6, 2011 to Official Action of Jan. 6, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/656,048.180Response Dated Mar. 22, 2011 to Final Notice of the Reason for Rejection of Nov. 24, 2010 From the Korean Intellectual Property Office Re.: Application No. 2009-7024590.181Response Dated Mar. 24, 2011 to Communication Pursuant to Article 94(3) EPC of Nov. 24, 2010 From the European Patent Office Re. Application No. 07789958.1.182Response Dated Mar. 3, 2010 to Official Action of Feb. 16, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/585,021.183Response Dated Mar. 9, 2011 to Official Action of Dec. 14, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/585,021.184Response Dated May 1, 2006 to Official Action of Mar. 30, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/808,541.185Response Dated May 5, 2011 to Requisition by the Examiner of Nov. 8, 2010 From the Canadian Intellectual Property Office Re. Application No. 2,461,663.186Response Dated Nov. 15, 2006 to Official Action of Jul. 25, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/808,541.187Response Dated Nov. 16, 2010 to Examination Report of Aug. 25, 2010 From the Instituto Mexicano de la Propriedad Industrial Re. Application No. PA/a/2004/002912.188Response Dated Nov. 23, 2009 to Office Action of Jul. 23, 2009 From the Israel Patent Office Re.: Application No. 199877.189Response Dated Nov. 24, 2011 to Official Action of Aug. 25, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/655,048.190Response Dated Nov. 28, 2010 to Office Action of Jul. 27, 2010 From the Israel Patent Office Re.: Application No. 199877.191Response Dated Nov. 8, 2010 to Office Action of Jul. 12, 2010 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200780033294.6.192Response Dated Oct. 13, 2008 to Official Action of Sep. 16, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/005,342.193Response Dated Oct. 19, 2011 to Official Action Dated Aug. 5, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/764,124.194Response Dated Oct. 23, 2011 to Office Action Dated May 17, 2011 From the Israel Patent Office Re.: Application No. 187892.195Response Dated Oct. 3, 2011 to Examination Report of Jun. 8, 2011 From the Instituto Mexicano de la Propriedad Industrial Re. Application No. MX/a/2007/015511.196Response Dated Oct. 3, 2011 to Office Action of Jun. 6, 2010 From the Israeli Patent Office Re.: Application No. 161083.197Response Dated Oct. 5, 2010 to Official Action of Jun. 17, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/585,021.198Response Dated Sep. 1, 2010 to Office Action of Apr. 25, 2010 From the Israel Patent Office Re.: Application No. 187892.199Response Dated Sep. 18, 2011 to Examination Report of Jun. 16, 2011 From the Instituto Mexicano de la Propriedad Industrial Re. Application No. PA/a/2006/010924.200Response Dated Sep. 7, 2011 to Official Action of Jul. 12, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 11/921,578.201Sakamoto et al. "Studies on Prodrugs. VI. Preparation and Characterization of 95-Substituted 2-Oxo-1,3-Dioxo1-4-yl)Methyl Esters of Mecillinam", Chemical and Pharmaceutical Bulletin, 35(2): 642-646, 1987. Abstract.202Sakamoto et al. "Studies on Prodrugs. VI. Preparation and Characterization of 95-Substituted 2-Oxo-1,3-Dioxol-4-yl)Methyl Esters of Mecillinam", Chemical and Pharmaceutical Bulletin, 35(2): 642-646, 1987. Abstract.203Scriba "Phenytoin-Lipid Conjugates as Potential Prodrugs of Phenytoin", Archiv der Pharmazie, VCH-Verlagsgesellschaft MBH, Weinheim, DE, 326(8): 477-481, 1993. Scheme 1, p. 147.204Scriba "Phenytoin-Lipid Conjugates as Potential Prodrugs of Phenytoin", Archiv der Pharmazie, VCH—Verlagsgesellschaft MBH, Weinheim, DE, 326(8): 477-481, 1993. Scheme 1, p. 147.205Scriba et al "Anticonvulsant Activity of Phenytoin-Lipid Conjugates, A New Class of Phenytoin Prodrugs"-Journal of Pharmaceutical Pharmacology, 47: 197-203, 1996. Scheme 1, p. 198, Abstract.206Scriba et al "Anticonvulsant Activity of Phenytoin-Lipid Conjugates, A New Class of Phenytoin Prodrugs"—Journal of Pharmaceutical Pharmacology, 47: 197-203, 1996. Scheme 1, p. 198, Abstract.207Scriba et al. "Synthesis and Anticovulsant Activity of N-Benzyloxycarbonyl-Amino Acid Prodrugs of Phenytoin", Journal of Pharmacy and Pharmacology, 51: 549-553, 1999.208Shalitin et al. "The Effect of Angiotensin II on Myosin Heavy Chain Expression in Cultured Myocardial Cells", In Vitro Cellular Development Biology-Animal, 32: 573-578, 1996.209Shalitin et al. "The Effect of Angiotensin II on Myosin Heavy Chain Expression in Cultured Myocardial Cells", In Vitro Cellular Development Biology—Animal, 32: 573-578, 1996.210Summons to Attend Oral Proceedings Pursuant to Rule 115(1) EPC Dated Jan. 26, 2012 From the European Patent Office Re. Application No. 06756205.8.211Supplemental After Final Amendment Dated Nov. 17, 2011 in Response to Official Action Dated Aug. 5, 2011 From the US Patent and Trademark Office Re. U.S. Appl. No. 12/764,124.212Supplemental Response Dated Mar. 31, 2009 to Response of Feb. 24, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/005,342.213Supplementary European Search Report Dated Apr. 25, 2006 From the European Patent Office Re.: Application No. 02772790.8.214Toth "A Novel Chemical Approach to Drug Delivery: Lipidic Amino Acid Conjugates", Journal of Drug Targeting, 2(3): 217-239, 1994. p. 223, col. II, 3rd �.215Translation of Final Notice of the Reason for Rejection Dated Aug. 31, 2011 From the Korean Intellectual Property Office Re. Application No. 2010-7016372.216Translation of Final Notice of the Reason for Rejection Dated Nov. 24, 2010 From the Korean Intellectual Property Office Re.: Application No. 2009-7024590.217Translation of Notice for Reason for Rejection Dated Oct. 20, 2009 From the Japanese Patent Office Re.: Application No. 2003-530202.218Translation of Notice of Final Rejection Dated May 30, 2011 From the Korean Intellectual Property Office Re. Application No. 2010-7016372.219Translation of Notice of Final Rejection Dated May 30, 2011 From the Korean Intellectual Property Office Re.: Application No. 2009-7024590.220Translation of Notice of Reason for Rejection Dated 30, Sep. 2011 From the Japanese Patent Office Re. Application No. 2007-504560.221Translation of Notice of Reason for Rejection Dated Feb. 10, 2009 From the Japanese Patent Office Re.: Application No. 2003-530202.222Translation of Notice of Reason for Rejection Dated Nov. 2, 2010 From the Japanese Patent Office Re. Application No. 2007-504560.223Translation of Notice of Reason for Rejection Dated Nov. 29, 2011 From the Japanese Patent Office Re. Application No. 2008-515378.224Translation of Notice of the Reason for Rejection Dated Aug. 26, 2009 From the Korean Intellectual Property Office Re.: Application No. 2004-7004581.225Translation of Notice of the Reason for Rejection Dated Feb. 24, 2010 From the Korean Intellectual Property Office Re.: Application No. 2009-7024590.226Translation of Notice of the Reason for Rejection Dated Mar. 26, 2010 From the Korean Intellectual Property Office Re.: Application No. 2004-7004581.227Translation of Notice of the Reason for Rejection Dated Oct. 28, 2010 From the Korean Itellectual property Office Re. Application No. 2010-7016372.228Translation of Office Action Dated Aug. 11, 2010 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200810190781.X.229Translation of Office Action Dated Feb. 23, 2012 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200780033294.6.230Translation of Office Action Dated Jan. 29, 2010 From the State Intellectual Property Office of the People's Republic of China Re.: Application No. 200680029378.8.231Translation of Office Action Dated Jan. 30, 2012 From the State Intellectual Property Office of the People's Republic of China Re.: Application No. 200680029378.8.232Translation of Office Action Dated Jan. 5, 2012 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200810190781.X.233Translation of Office Action Dated Jul. 12, 2010 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200780033294.6.234Translation of Office Action Dated Jul. 17, 2009 From the State Intellectual Property Office of the People's Republic of China Re.: Application No. 200580017025.1.235Translation of Office Action Dated Nov. 3, 2011 From the State Intellectual Property Office of the People's Republic of China Re.: Application No. 200580017025.1.236Vel�zquez et al. "Butyrate Inhibits Seeding and Growth of Colorectal Metastases to the Liver in Mice", Surgery, XP005473855, 120(2): 440-448, Aug. 1, 1996. Abstract.237Vezin et al. "Biological Active Poly(N-Metacryloyl-ω-Amino Acid) Esters of Fluphenazine and Their Duration of Activity", Journal of Pharmacy and Pharmacology, British Pharmacology Conference 1979, 31(Suppl.): 63P, 1979.238Ware et al. "An Automated Approach to Salt Selection for New Unique Trazodone Salts", Pharmaceutical Research, 21(1): 177-184, 2004. Abstract.239Wilson et al. "Central Nervous System Depressant", Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, 8th Ed., p. 362-371, 1982.240Wolffe "Transcriptional Control. Sinful Repression", Nature, 387: 16017, 1997.241Worms et al. "Dopamine-Like Activities of an Aminopyridazinde Derivative, CM 30366: A Behavioural Study", Naunyn-Schmiedeberg's Archives of Pharmacology, 334: 246-252, 1986.242Written Opinion Dated Aug. 23, 2006 From the international Searching Authority Re.: Application No. PCT/IL2005/000341.243Written Opinion Dated Feb. 12, 2008 From the International Searching Authority Re.: Application No. PCT/IL2007/000903.244Written Opinion Dated Feb. 13, 2008 From the International Searching Authority Re.: Application No. PCT/IL2007/000902.245Written Opinion Dated Jun. 25, 2009 From the International Searching Authority Re.: Application No. PCT/IL2009/000158.246Yogev-Falach et al. "The Importance of Propargylamine Moiety in the Anti-Parkinson Drug Rasagiline and Its Derivatives in MAPK-Dependent Amyloid Precursor Protein Processing", The FASEB Journal, 17: 2325-2327, 2003. Abstract.247Zaugg et al. "Modification of Hemoglobin With Analogs of Aspirin", The Journal of Biological Chemistry, 255(7): 2816-2821, 1980.* Cited by examinerClassifications U.S. Classification514/551, 560/130, 560/142International ClassificationC07C69/00, A61K31/22Cooperative ClassificationA61K45/06, A61K47/481European ClassificationA61K47/48H4Q, A61K45/06Legal EventsDateCodeEventDescriptionFeb 22, 2010ASAssignmentOwner name: BAR-ILAN UNIVERSITY,ISRAELFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NUDELMAN, ABRAHAM;REEL/FRAME:023966/0533Effective date: 20081130Owner name: BIOLINERX LTD.,ISRAELFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIFSHITZ, RAN;WINKLER, ILAN;REEL/FRAME:023966/0535Effective date: 20081204Owner name: RAMOT AT TEL AVIV UNIVERSITY LTD.,ISRAELFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:REPHAELI, ADA;GIL-AD, IRIT;WEIZMAN, ABRAHAM;SIGNING DATES FROM 20081127 TO 20081217;REEL/FRAME:023966/0591Owner name: BAR-ILAN UNIVERSITY, ISRAELFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NUDELMAN, ABRAHAM;REEL/FRAME:023966/0533Effective date: 20081130Owner name: BIOLINERX LTD., ISRAELFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIFSHITZ, RAN;WINKLER, ILAN;REEL/FRAME:023966/0535Effective date: 20081204Owner name: RAMOT AT TEL AVIV UNIVERSITY LTD., ISRAELFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:REPHAELI, ADA;GIL-AD, IRIT;WEIZMAN, ABRAHAM;SIGNING DATES FROM 20081127 TO 20081217;REEL/FRAME:023966/0591Feb 26, 2016REMIMaintenance fee reminder mailedRotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services